Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells.

Dendritic cells (DCs) and myeloid-derived suppressor cells (MDSCs) show opposing roles in the immune system. In the present study, we report that the establishment of a positive feedback loop between prostaglandin E(2) (PGE(2)) and cyclooxygenase 2 (COX2), the key regulator of PGE(2) synthesis, represents the determining factor in redirecting the development of CD1a(+) DCs to CD14(+)CD33(+)CD34(+) monocytic MDSCs. Exogenous PGE(2) and such diverse COX2 activators as lipopolysaccharide, IL-1β, and IFNγ all induce monocyte expression of COX2, blocking their differentiation into CD1a(+) DCs and inducing endogenous PGE(2), IDO1, IL-4Rα, NOS2, and IL-10, typical MDSC-associated suppressive factors. The addition of PGE(2) to GM-CSF/IL-4-supplemented monocyte cultures is sufficient to induce the MDSC phenotype and cytotoxic T lymphocyte (CTL)-suppressive function. In accordance with the key role of PGE(2) in the physiologic induction of human MDSCs, the frequencies of CD11b(+)CD33(+) MDSCs in ovarian cancer are closely correlated with local PGE(2) production, whereas the cancer-promoted induction of MDSCs is strictly COX2 dependent. The disruption of COX2-PGE(2) feedback using COX2 inhibitors or EP2 and EP4 antagonists suppresses the production of MDSC-associated suppressive factors and the CTL-inhibitory function of fully developed MDSCs from cancer patients. The central role of COX2-PGE(2) feedback in the induction and persistence of MDSCs highlights the potential for its manipulation to enhance or suppress immune responses in cancer, autoimmunity, or transplantation.

[1]  B. Rini,et al.  Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. , 2011, Neuro-oncology.

[2]  G. Lesinski,et al.  Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy , 2011, Cancer Immunology, Immunotherapy.

[3]  W. Fellows-Mayle,et al.  COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. , 2011, Cancer research.

[4]  A. Algra,et al.  Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials , 2010, The Lancet.

[5]  J. Vieweg,et al.  Pivotal Advance: Tumor‐mediated induction of myeloid‐derived suppressor cells and M2‐polarized macrophages by altering intracellular PGE2 catabolism in myeloid cells , 2010, Journal of leukocyte biology.

[6]  Y. Shoenfeld,et al.  Tolerogenic dendritic cells in autoimmune diseases: crucial players in induction and prevention of autoimmunity. , 2010, Autoimmunity reviews.

[7]  H. Hoogsteden,et al.  COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function , 2010, BMC Cancer.

[8]  Bali Pulendran,et al.  Programming dendritic cells to induce TH2 and tolerogenic responses , 2010, Nature Immunology.

[9]  H. Ueno,et al.  Dendritic Cells: Are They Clinically Relevant? , 2010, Cancer journal.

[10]  A. Dietz,et al.  Immunosuppressive CD14+HLA‐DRlow/− monocytes in prostate cancer , 2010, The Prostate.

[11]  M. Manns,et al.  Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor , 2009, Hepatology.

[12]  A. Harris,et al.  Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia. , 2009, Blood.

[13]  T. Padhya,et al.  Mechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells1 , 2009, The Journal of Immunology.

[14]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[15]  Xuetao Cao,et al.  Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF-β11 , 2009, The Journal of Immunology.

[16]  Yuan Zhang,et al.  B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer. , 2008, Clinical immunology.

[17]  M. Manns,et al.  A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. , 2008, Gastroenterology.

[18]  L. Mariani,et al.  Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P. Sinha,et al.  Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. , 2007, Cancer research.

[20]  S. Narumiya,et al.  Prostaglandin E Receptors* , 2007, Journal of Biological Chemistry.

[21]  P. Rodriguez,et al.  Arginase, Prostaglandins, and Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[22]  D. Gabrilovich,et al.  Tumor Associated CD8+ T-Cell Tolerance Induced by Bone Marrow Derived Immature Myeloid Cells , 2005 .

[23]  S. Dubinett,et al.  Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma , 2005, The Journal of experimental medicine.

[24]  D. Gabrilovich,et al.  Tumor-Associated CD8+ T Cell Tolerance Induced by Bone Marrow-Derived Immature Myeloid Cells1 , 2005, The Journal of Immunology.

[25]  V. Bronte,et al.  Regulation of immune responses by L-arginine metabolism , 2005, Nature Reviews Immunology.

[26]  Weiping Zou,et al.  Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.

[27]  D. Gabrilovich Mechanisms and functional significance of tumour-induced dendritic-cell defects , 2004, Nature Reviews Immunology.

[28]  W. Isaacs,et al.  Cyclooxygenases in cancer: progress and perspective. , 2004, Cancer letters.

[29]  D. Munn,et al.  Ido expression by dendritic cells: tolerance and tryptophan catabolism , 2004, Nature Reviews Immunology.

[30]  Ruslan Medzhitov,et al.  Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis , 2004, Cell.

[31]  T. Curiel,et al.  Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.

[32]  M. Huang,et al.  Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  Jeonghee Cho,et al.  Induction of COX‐2 by LPS in macrophages is regulated by Tpl2‐dependent CREB activation signals , 2002, The EMBO journal.

[34]  M. Colonna,et al.  Tolerization of dendritic cells by TS cells: the crucial role of inhibitory receptors ILT3 and ILT4 , 2002, Nature Immunology.

[35]  V. Bronte,et al.  Tumor-induced immune dysfunctions caused by myeloid suppressor cells. , 2001, Journal of immunotherapy.

[36]  H. Hollema,et al.  Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. , 2001, Cancer research.

[37]  A. Mancini,et al.  Prostaglandin E2 Regulates the Level and Stability of Cyclooxygenase-2 mRNA through Activation of p38 Mitogen-activated Protein Kinase in Interleukin-1β-treated Human Synovial Fibroblasts* , 2001, The Journal of Biological Chemistry.

[38]  J. Banchereau,et al.  Sensing Pathogens and Tuning Immune Responses , 2001, Science.

[39]  J. Banchereau,et al.  IL-6 switches the differentiation of monocytes from dendritic cells to macrophages , 2000, Nature Immunology.

[40]  K. Ozato,et al.  Interferon Regulatory Factor (Irf)-1 and Irf-2 Regulate Interferon γ–Dependent Cyclooxygenase 2 Expression , 2000, The Journal of experimental medicine.

[41]  Milton W. Taylor,et al.  Indoleamine 2,3-Dioxygenase Production by Human Dendritic Cells Results in the Inhibition of T Cell Proliferation , 2000, The Journal of Immunology.

[42]  P. Kalinski,et al.  T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. , 1999, Immunology today.

[43]  J. Blay,et al.  Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. , 1998, Blood.

[44]  D. Carbone,et al.  Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. , 1998, Blood.

[45]  P. Kalinski,et al.  Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. , 1998, Journal of immunology.

[46]  H. Klocker,et al.  Prostaglandin E2 and Tumor Necrosis Factor α Cooperate to Activate Human Dendritic Cells: Synergistic Activation of Interleukin 12 Production , 1997, The Journal of experimental medicine.

[47]  P. Kalinski,et al.  IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. , 1997, Journal of immunology.

[48]  A. Lanzavecchia,et al.  A Novel Inhibitory Receptor (ILT3) Expressed on Monocytes, Macrophages, and Dendritic Cells Involved in Antigen Processing , 1997, The Journal of experimental medicine.

[49]  J. Ceuppens,et al.  Regulation of the immune response by prostaglandins , 1983, Journal of Clinical Immunology.

[50]  D. Gabrilovich,et al.  Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. , 2011, Trends in immunology.

[51]  H. Klocker,et al.  Prostaglandin E2 and Tumor Necrosis Factor ␣ Cooperate to Activate Human Dendritic Cells: Synergistic Activation of Interleukin 12 Production , 1997 .